LABU Fees and Costs — Direxion Daily S&P Biotech Bull 3X Shares
Data updated: 2026-09-28
The net expense ratio is 0.93%. There are no sales loads or redemption fees. In fiscal 2025 the fund paid $2.4M in broker commissions, 0.3400% of average net assets, and portfolio turnover was 179%.
LABU Fees and Expenses
Annual operating expenses and sales charges of LABU. Prospectus, as of February 28, 2025.
| Annual operating expenses | |
|---|---|
| Management fee | 0.75% |
| 12b-1 fee | 0.00% |
| Other expenses | 0.16% |
| Gross expense ratio | 0.93% |
| Fee waiver | — |
| Net expense ratio | 0.93% |
| Sales charges | |
|---|---|
| Max front load | — |
| Max deferred load | — |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | No |
| Waived fees subject to recoupment | Yes |
LABU Costs Over Time
On $10,000 invested in LABU, assuming 5% a year before costs, total costs come to $790 over 5 years, cutting the return by 1.33% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 0.93%) | $98 | $304 | $525 |
| Trading costs (broker commissions) | $36 | $111 | $192 |
| Lost growth on money paid in costs | $0 | $21 | $73 |
| Total costs | $133 | $435 | $790 |
| Value after costs | $10,367 | $11,141 | $11,973 |
| Impact on return, per year | 1.33% | 1.33% | 1.33% |
LABU Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending October 31, 2025.
- Explicit cost rate (commissions ÷ average net assets): 0.3400%
- Total broker commissions: $2.4M
- Bought from dealers (principal trades, not a cost): —
- Portfolio turnover (prospectus): 179%
- Securities on loan, average value: $27.4M
- Net income from securities lending: $369K (0.053% of average net assets)
LABU Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| Citibank, National Association | $949K | 39.80% |
| Barclays Bank PLC | $605K | 25.35% |
| Goldman Sachs & Co. LLC | $246K | 10.31% |
| UBS AG | $184K | 7.70% |
| JPMorgan Chase Bank, National Association | $161K | 6.75% |
| Bank of America N.A. | $146K | 6.10% |
| BNP Paribas | $95K | 3.99% |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.